If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
You need a JavaScript-enabled browser to view this Publication
Please follow these steps to view the Publication:
Enable JavaScript in your browser
Refresh this page
Best regards
Zmags
HEPATOLOGY
ISSN 2053-4221 May 2014 • emjreviews.com
INSIDE
Review of
ILC 2014
London, UK
SOVALDI® transforms HCV therapy, allowing
more adult patients the opportunity of cure
In clinical trials
· The first approved nucleotide polymerase inhibitor with pan-genotypic
activity and a high barrier to resistance1
· ≥90% of treatment-naïve adults, across all genotypes are cured with 12 weeks
of SOVALDI + Peg-IFN + RBV (No Peg-IFN required for GT 2)1
· The first all-oral 24-week option across all genotypes for those unsuitable for IFN
(12-24 week treatment duration for GT 2)1
· No specific adverse drug reactions identified for SOVALDI within SOVALDI + RBV
± Peg-IFN regimens1
SOVALDI is indicated in combination with other medicinal
products for the treatment of chro
HEPATOLOGY ISSN 2053-4221
SOVALDI® transforms HCV therapy, allowing more a
CONTENTS EDITORIAL BOARD.......................
HEPATOLOGY USE OF HBSAG QUANTIFICATION TO GUID
Editorial Board Hepatology Editor-in-Chief: Pr
Welcome Spring has now sprung, as has our second
European Medical Journal Hepatology May 2014 P
Foreword Univ Prof Dr Markus Peck-Radosavljevic
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Welcome to the European Medical Journal review of
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
The presentation of these new, direct-acting, ant
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Potential Hepatitis C cure blooms in Chinese foli
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Confronting hepatitis C: a comprehensive approach
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Liver disease gets gutsy FAECAL microbiota tr
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
T cell clone wars ADOPTIVE T cell therapy could b
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Hepatic encephalopathy is not the end of the road
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Host of therapeutic options to improve HCC patien
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Fatty livers lead to dangerous hearts CARDIOVASCU
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Three against one: the attack on hepatitis B EXPE
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Triangle of action against hepatitis C “These dat
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Hepatitis C drug shows glittering prowess through
ILC ANNUAL CONGRESS 2014 EXCEL LONDON EXHIBITION
Bristol-Myers Squibb: at the Core of HCV Research
TRANSFORMING HCV MANAGEMENT Summary of Presentati
development of the second-generation - more
Initial treatment regimens with IFN
Perspectives on Therapy for Challenging Pa
demonstrated up to 98% SVR for GT1 patients in a
data. AASLD 1–5 November 2013, Washington
NEWS AT SIX: HEPATITIS C SPECIAL Summary of Pre
lower against HCV GT 3 and they possess a
of RBV, must be taken into account.12 Care
Discrimination and practical difficulties
transplantation,50 and with current therapies the
MK-5172/MK-8742 +/- RBV for 12 weeks in HCV genot
TRANSLATION FROM MICE TO MEN: ARE DOGS A
Requirements for Animal Models Important requirem
Table 1: Markers used to investigate mouse, dog o
Using a plate-and-wait method, colonies of canine
provides an excellent model for clinical HP
REFERENCES 1. Riehle KJ et al. New concepts in li
48. Kim H et al. Human hepatocellular carcinomas
OVERLAPPING CLINICAL FEATURES BETWEEN NAFLD
of specific signs of these diseases that ma
NAFLD GENETIC BACKGROUND CIRCULATING ADIPOCY
for the Kruppel-like factor 6 (KLF6), which
Although the real role of these two adipocytokine
either for establishing the primary determin
children with non-alcoholic fatty liver disea
ADIPOSE TISSUE, METABOLIC SYNDROME, AND NON- ALCO
the central role of adiposity in the patho
resistance is accompanied by hyperinsulinaemi
expanding its adipose tissue, thus these effects
Some examples include the UCP1 -3826 A>G po
interventions. Although randomised controll
the hepatic manifestation of MetS, while in patie
2001;96(10):2957–61. 40. Schwimmer JB et al. Prev
82. Sookoian S et al. Modest alcohol consum
COST-EFFECTIVE INTERVENTIONS IN THE CONTROL
have, as yet, introduced universal HBV vaccinatio
Table 1: Summary of recently published cost-effec
Intervention Country/Target Group Summary of
born abroad but are currently living in Canada. T
would cost to expand the coverage of existing r
USE OF HBSAG QUANTIFICATION TO GUIDE HBIG PROPHYL
from high-dose intravenous (i.v.) HBIG - administ
complications) or in patients with HCC and
mIU/mL at day 7. The secondary endpoints were: ev
HCC was present in 24 (58.5%) and H
Table 3: Univariate comparison between efficacy p
DISCUSSION In the setting of LT for HBsAg-relate
30,000 IU HBIG (p=0.0002) and underwent further b
recurrent hepatitis B virus by vaccination after
LIVER TRANSPLANTATION FOR ALCOHOLIC LIVER
Recently, increased risk of mortality due to live
European Association for the Study of the Liver (
CONCLUSION LT for alcoholic cirrhosis is a matte
physical complications. London: Royal College
ACUTE LIVER FAILURE: A DANGEROUS AND
Acute liver failure (ALF) -Recovery under conse
A Acute liv
Table 1: Aetiologies of acute liver failure (ALF)
of inflammatory cells.31 However, apoptosis itself
Table 2: Scoring systems in patients with acute l
of novel markers and diagnostic methods should be
consumption ingesting paracetamol at the
ACUTE LIVER FAILURE: PATHOPHYSIOLOGIC BASIS, A
ALF is a rare condition, with a reported annual i
blood flow (CBF) and cerebral autoregulation,
Controversy continues to rage about the use of IC
Infections and Sepsis in ALF Immune paralysis,
such as ventilator associated pneumonias, acute l
subacute ALF), are occasionally used. Although th
muscles as phenylacetylglutamine (PAGN), and
hyperammonemia to cerebral edema. Metab Brain
WHAT’S NEW: INTERVIEW Sovaldi®: winning the battl
HEPATOLOGY molecule is being targeting to be cov
WHAT’S NEW New liver
HEPATOLOGY Transforming skin cells into liver cel
WHAT’S NEW Mysterious mutation causing liver canc
HEPATOLOGY New budding treatment for hepatitis B
WHAT’S NEW Topiramate, curbing alcohol consumptio
HEPATOLOGY From stem cells to pure liver and panc
WHAT’S NEW Preventing the lethal consequences of
HEPATOLOGY Zebrafish model used to detect new canc
WHAT’S NEW Last-minute holiday deals may harm liv
HEPATOLOGY Omega-3 fighting fatty liver disease OM
WHAT’S NEW Stop blaming fructose for NAFLD FRUCTO
HEPATOLOGY Mood-stabilising drug to treat ATD
WHAT’S NEW Breakthrough potential hepatitis C vac
HEPATOLOGY Saliva protein reducing mortality in A
WHAT’S NEW GPB shows promise for cirrhosis patien
A HISTORY OF INNOVATION. A COMMITMENT TO CHRONIC
Featured Suppliers Hepatology Almirall is an in
Bristol-Myers Squibb: at the Core of HCV Research
Buyer’s Guide & Societies Exhibitors • ABBOTT
Hepatology Partner Associations • AASLD - AMER
UPCOMING EVENTS International Liver Transplantat
HEPATOLOGY European Association for the Study of
From a host of fifteen therapeutic areas, EUROPEAN